PATENT CLAIM ANALYSIS

Application Number: 16024226
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-11
Patent Classification: ["424", "134100"]

Abstract:
The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects.

Claim (Index 71):
A recombinant fusion protein comprising:\n (a) a first domain comprising a portion of T-cell immunoglobulin mucin receptor 3 (TIM-3) comprising the amino acid sequence of SEQ ID NO: 36 and is capable of binding a TIM-3 ligand, (b) a second domain comprising a portion of CD40 ligand (CD40L) comprising the amino acid sequence of SEQ ID NO: 60 and is capable of binding a CD40L receptor, and (c) a linker linking the first domain and the second domain and comprising a hinge-CH2-CH3 Fc domain.

Metadata:
- Claim Count in Document: 74.0
- Percentile: 94.0
- Lexical Diversity: 1.34091
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15853241', '16024228', '16024214', '16024218', '16024209']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8538323194974139
- 35 USC 102 Novelty (BERT): 0.6726743119613401
- Combined Prediction Score: 0.8357165187438065
- Mean Citation Score: 705.327062
- Max Citation Score: 733.3173
- Similarity Product: 656.6907592637657

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test